Abstract
From the interruption of clinical trials by shelter-in-place orders to the challenges involved in safely collecting biofluid samples, drug development for neurological disease was hit hard by the COVID-19 pandemic this year. However, the field has responded with innovative solutions, and 2021 could see the therapeutic pipeline flowing again.
All Keywords
【초록키워드】 clinical trial, Drug development, COVID-19 pandemic, clinical trials, therapeutic, Neurological disease, interruption, involved, 【제목키워드】 COVID-19, therapeutic,
【초록키워드】 clinical trial, Drug development, COVID-19 pandemic, clinical trials, therapeutic, Neurological disease, interruption, involved, 【제목키워드】 COVID-19, therapeutic,
{{{ 추상적인 }}}
자택 대피 명령으로 인한 임상 시험 중단부터 생체 유체 샘플을 안전하게 수집하는 문제에 이르기까지 올해 코로나19 팬데믹으로 신경계 질환 치료제 개발이 큰 타격을 입었습니다. 그러나 이 분야는 혁신적인 솔루션으로 대응했으며 2021년에는 치료 파이프라인이 다시 흐르는 것을 볼 수 있습니다.